These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37209611)

  • 1. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Analysis of Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Zhejiang, China.
    Liu Z; Zhang M; Wang J; Chen S; Wu B; Zhou L; Pan A; Wang W; Wang X
    Biomed Res Int; 2020; 2020():3159482. PubMed ID: 32104686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    De Vos E; Scott L; Voss De Lima Y; Warren RM; Stevens W; Hayes C; da Silva P; Van Rie A
    Int J Tuberc Lung Dis; 2021 Feb; 25(2):134-141. PubMed ID: 33656425
    [No Abstract]   [Full Text] [Related]  

  • 6. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh.
    Hossain ST; Isaakidis P; Sagili KD; Islam S; Islam MA; Shewade HD; Kamal SM; Husain A
    PLoS One; 2015; 10(6):e0129155. PubMed ID: 26110273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
    Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
    Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment attrition and treatment initiation delay among rifampicin-resistant tuberculosis patients in Lagos, Nigeria: a retrospective cohort study.
    Adejumo OA; Daniel O; Adepoju VA; Onoh MO; Sokoya OD; Abdur-Razzaq H; Moronfolu O; Oyadotun OM; Olusola-Faleye B
    Trans R Soc Trop Med Hyg; 2022 Dec; 116(12):1154-1161. PubMed ID: 35710310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China.
    Liang L; Wu Q; Gao L; Hao Y; Liu C; Xie Y; Sun H; Yan X; Li F; Li H; Fang H; Ning N; Cui Y; Han L
    Thorax; 2012 Jul; 67(7):632-8. PubMed ID: 22403070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
    Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
    Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.
    Abraham Y; Assefa DG; Hailemariam T; Gebrie D; Debela DT; Geleta ST; Tesfaye D; Joseph M; Manyazewal T
    BMC Infect Dis; 2024 Oct; 24(1):1087. PubMed ID: 39354416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China.
    Zhu QQ; Wang J; Sam NB; Luo J; Liu J; Pan HF
    Med Sci Monit; 2022 Apr; 28():e935334. PubMed ID: 35437301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.